Search
項目搜尋
結構搜尋
Thermo Scientific Chemicals
Moxifloxacin hydrochloride
Moxifloxacin hydrochloride, CAS # 186826-86-8, is a broad-spectrum compound with antibacterial activity against both gram-positive and gram-negative bacteria. It also shows inhibitory activity against topoisomerase II.
| 產品號碼 | Quantity |
|---|---|
| 457960010 | 1 g |
化學識別
CAS186826-86-8
IUPAC Namehydrogen 1-cyclopropyl-6-fluoro-8-methoxy-7-{octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl}-4-oxo-1,4-dihydroquinoline-3-carboxylic acid chloride
Molecular FormulaC21H25ClFN3O4
InChI KeyIDIIJJHBXUESQI-UHFFFAOYNA-N
SMILES[H+].[Cl-].COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CC2CCCNC2C1)C1CC1
檢視更多
規格
規格表
規格表Appearance (Color)Almost white to yellow
Appearance (Form)Powder
Infrared spectrumConforms
HPLC>=97.5 %
Water=<5 %
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
• Moxifloxacin hydrochloride is a fourth-generation synthetic fluoroquinolone compound with antibacterial activity against both gram-positive and gram-negative bacteria
• It also shows an inhibitory activity against topoisomerase II
• Moxifloxacin hydrochloride can bind to and inhibit both bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in DNA replication and repair inhibition thus induce cell death in sensitive bacterial species
• Moxifloxacin has 100 times higher affinity for bacterial DNA gyrase compared to mammalian DNA gyrase
Applications
• Moxifloxacin hydrochloride presents a higher anti-gram-positive activity compared to other fluoroquinolone such as ciprofloxacin and ofloxacin
• It has immunosuppressive activity that inhibits the proliferation of all classes of lymphocytes, which can induce apoptosis of antigen-presenting T cells
• It is a cytostatic anthracenedione that can intercalate DNA, increasing the occurence of double-strand breaks by stabilizing the cleavable complex of topoisomerase II and DNA
• This compound shows anticancer activity in some animal models presenting leukemia
• Moxifloxacin is being investigated for the treatment of multidrug-resistant tuberculosis strains
RUO – Research Use Only
Literature References
Omari, M.; Jaafari, D.; Al-Sou'od, K.; Badwan, A. Moxifloxacin hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014, 39, 299-431. Gillespie, S.H. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev. 2016, 25, (139), 19-28.
Chan, E.D; Laurel, V.; Strand, M.J.; Chan, J.F.;; Huynh, M.L.; Goble, M.; Iseman M.D. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004, 169, (10), 1103-9. Iatropoulos, M.J.; Jeffrey, A.M.; Enzmann, H.G.; von Keutz, E.; Schlueter, G.; Williams, G.M. Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic. Exp Toxicol Pathol. 2001, 53, (5), 345-57.
Yadav, V.; Talwar, P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomed Pharmacother. 2019, 111, 934-946.